Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:methylphenidate
|
| gptkbp:approvalYear |
2000
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N06BA04
|
| gptkbp:brand |
gptkb:methylphenidate_extended-release
|
| gptkbp:contraindication |
anxiety
glaucoma tics hypersensitivity to methylphenidate |
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II_(US)
|
| gptkbp:eliminatedIn |
urine
|
| gptkbp:form |
extended-release tablet
|
| gptkbp:genericAvailable |
yes
|
| gptkbp:halfLife |
3.5 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Concerta
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:marketedIn |
gptkb:Canada
gptkb:Europe gptkb:United_States |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
headache
increased heart rate insomnia dry mouth decreased appetite |
| gptkbp:usedFor |
gptkb:attention_deficit_hyperactivity_disorder
narcolepsy |
| gptkbp:bfsParent |
gptkb:Ritalin
|
| gptkbp:bfsLayer |
5
|